Singular Genomics Systems IncNASDAQ:OMICNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.4041
- TODAY'S CHANGE (%)-0.0104 (-2.4976%)
- Bid / Lots0.3981/ 7
- Ask / Lots0.4100/ 45
- Open / Previous Close0.4200 / 0.4144
- Day Range
- 52 Week Range
- Volume7,397
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OMIC |
|---|---|---|
| 09:32 ET | 620 | 0.42 |
| 09:39 ET | 2371 | 0.4198 |
| 09:54 ET | 236 | 0.409 |
| 09:56 ET | 780 | 0.4253 |
| 09:59 ET | 300 | 0.409 |
| 10:24 ET | 1204 | 0.40405 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Singular Genomics Systems Inc | 30.6M | -0.3x | --- |
Dare Bioscience Inc | 29.9M | -0.8x | --- |
Lipocine Inc | 25.5M | -1.5x | --- |
Addex Therapeutics Ltd | 27.4M | -0.1x | --- |
Marker Therapeutics Inc | 39.4M | -2.8x | --- |
Synlogic Inc | 22.2M | -0.2x | --- |
Company Information
Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The Company has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine consists of proprietary chemistry, including novel chemical compounds, polymers, and enzymes. Its active product development pipeline consists of two products, each of which is designed to leverage the Sequencing Engine and purpose-built to address different applications. Its first product, the G4 Sequencing Platform (G4), targets the NGS market. Its second product in development, G4X Spatial Sequencer, which leverages its sequencing technology, applying it as an in-situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. The Company is also engaged in developing PX, which is a development-stage multiomics platform.
Contact Information
- Headquarters
- 3010 SCIENCE PARK ROADSAN DIEGO, CA, United States 92121
- Phone
- 858-333-7830
- Fax
- 302-531-3150
Executives
- Chairman of the Board, President, Chief Executive Officer, Founder
- Andrew Spaventa
- Founder, Chief Scientific Officer
- Eli Glezer
- Chief Financial Officer
- Dalen Meeter
- Senior Vice President - Human Resources
- Vincent Brancaccio
- Senior Vice President - Corporate Development and Strategy
- Jorge Velarde
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $30.6M |
|---|---|
Revenue (TTM) | $2.9M |
Shares Outstanding | 73.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.30 |
Book Value | $2.42 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 10.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,531.47% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
